• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic Diabetes unit fully resolves FDA warning letter

April 25, 2023 By Sean Whooley

Medtronic World Diabetes Day
[Image from Medtronic]
Medtronic (NYSE:MDT) announced today that the FDA lifted the warning letter related to its Diabetes business unit headquarters.

In December 2021, the FDA issued a warning letter to Medtronic’s Northridge, California, Diabetes headquarters.

The letter centered around the inadequacy of specific medical device quality system requirements at the Northridge facility. It scrutinized the areas of risk assessment, corrective and preventive action and complaint handling. The letter also related to device recalls and the reporting of adverse events.

At the time, Medtronic said the inspection related to recalls of its MiniMed 600 series insulin infusion pump. It also related to a remote controller device for MiniMed 508 and Paradigm pumps. Medtronic first warned of safety problems with the MiniMed 600 pumps in November 2019. The recall initially involved 322,005 MiniMed 630G and MiniMed 670G pumps in the U.S.

In October 2021, the company expanded the Class I recall. This action replaced all MiniMed 600 series insulin pumps that contain the clear container ring. That brought the total tally of devices recalled in the U.S. to 463,464.

Medtronic’s road to resolving the letter

Shortly after the company received the letter, CEO Geoff Martha said the letter likely would impact regulatory timelines for next-generation diabetes technologies. It may have done so, but just last week, the FDA approved the next-generation MiniMed 780G insulin pump with Guardian 4 sensor technology. Medtronic had said last fall that it achieved 90% of the FDA’s action items pertaining to the letter.

Medtronic said today that the resolution follows ongoing remediation from the company. It took proactive actions to continue to strengthen its quality systems, according to a news release. All regulatory restrictions associated with the letter are resolved, the company said.

“We’re very thankful to the agency for working with us so collaboratively to ensure we’re able to work as quickly as possible to address the needs of the diabetes community,” said Que Dallara, EVP and president of Medtronic Diabetes. “Clearing this latest regulatory milestone allows us to focus on what’s most important – delivering innovations that address unmet needs for the individuals with diabetes we have the privilege to serve.

“It’s an honor that we never take for granted and our commitment is to ensure we’re putting patients first and prioritizing safety and quality above all.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance, Technology Tagged With: FDA, Medtronic

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS